Biosimilars Quiz: Adalimumab Biosimilar ABP 501 Adherence, Switching Patterns

News
Article

Test your knowledge of treatment persistence, adherence, and switching patterns of adalimumab biosimilar ABP 501 between adalimumab-naïve patients and adalimumab-experienced patients.

A retrospective analysis examined pharmacy claims data from Germany and France, focusing on adult patients with inflammatory bowel disease (IBD) who initiated treatment with ABP 501, an adalimumab biosimilar, between October 2018 and March 2020. The study assessed treatment persistence, adherence, and switching patterns for two groups: adalimumab-naïve patients and adalimumab-experienced patients.

Test your knowledge of ABP 501 with this quiz:

What was the overall switch rate within the first 12 months of ABP 501 initiation in the French patient population?


Recent Videos
1 KOL is featured in this Insights series.
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
Discussing Post-Hoc Data on Ruxolitinib for Nonsegmental Vitiligo, with David Rosmarin, MD
1 KOL is featured in this series.
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.